Completion of the clinical phase of randomized, double blind, placebo controlled pilot study conducted in India to evaluate safety and efficacy of orally administered IMA001 in sickle cell disease patients.
Imalia Reports Initial Proof-of-Concept Data for IMA001 in Sickle Cell Disease Model
Imalia reports initial proof-of-concept data for the effect of IMA001,on the progression of markers